Hauser RA, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 2017;174(5):476-484.

https://pubmed.ncbi.nlm.nih.gov/28320223/

Correll CU, et al. Characterizing treatment effects of valbenazine for tardive dyskinesia: additional results from the KINECT 3 study. J Clin Psychiatry. 2018;18;80(1):18m12278.

https://pubmed.ncbi.nlm.nih.gov/30695293/

Marder SR, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39(6):620-627.

https://pubmed.ncbi.nlm.nih.gov/31688452/

Sajatovic M, et al. The effects of valbenazine on tardive dyskinesia in older and younger patients. Int J Geriatr Psychiatry. 2020;35(1):69-79.

https://pubmed.ncbi.nlm.nih.gov/31617235/

Caroff SN, et al. RE-KINECT: A prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. J Clin Psychopharmacol. 2020;40(3):259-268.

https://pubmed.ncbi.nlm.nih.gov/32332461/

Cutler AJ, et al. Caregiver-reported burden in RE-KINECT: data from a prospective real-world tardive dyskinesia screening study. J Am Psychiatr Nurses Assoc. 2021;22:10783903211023565.

https://pubmed.ncbi.nlm.nih.gov/34154444/

Stacy M, et al. Abnormal involuntary movement scale in tardive dyskinesia: minimally clinically important difference. Mov Disord. 2019;34(8):1203-1209.

https://pubmed.ncbi.nlm.nih.gov/31234240/

McIntyre RS, et al. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. J Affect Disord. 2019;246:217-223.

https://pubmed.ncbi.nlm.nih.gov/30583148/

Thai-Cuarto D, et al. Cardiovascular profile of valbenazine: analysis of pooled data from three randomized, double-blind, placebo-controlled trials. Drug Saf. 2018;41(4):429-440.

https://pubmed.ncbi.nlm.nih.gov/29218680/